The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant.
Standard
The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant. / Browne, E; Cressey, D M; Agarwal, Kamayni; Cosgrove, J F.
in: ANAESTHESIA, Jahrgang 62, Nr. 3, 3, 2007, S. 282-285.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant.
AU - Browne, E
AU - Cressey, D M
AU - Agarwal, Kamayni
AU - Cosgrove, J F
PY - 2007
Y1 - 2007
N2 - Drotrecogin alfa has been shown to reduce mortality in severe sepsis. However, it remains unlicensed for use in patients with previous liver transplantation. We report its use in such a case. Prior to administration a risk benefit analysis was performed in line with General Medical Council recommendations. This included being satisfied that no appropriately licensed alternative would better serve the patient's needs and that sufficient evidence existed to demonstrate the safety and efficacy of the drug. Responsibility was taken for prescription, monitoring and follow up. The process was carefully documented and the patient recovered fully with no adverse effects. To date the only published data on the use of drotrecogin alpha in transplant recipients is a case series of three patients. Further published data may encourage review of the licence.
AB - Drotrecogin alfa has been shown to reduce mortality in severe sepsis. However, it remains unlicensed for use in patients with previous liver transplantation. We report its use in such a case. Prior to administration a risk benefit analysis was performed in line with General Medical Council recommendations. This included being satisfied that no appropriately licensed alternative would better serve the patient's needs and that sufficient evidence existed to demonstrate the safety and efficacy of the drug. Responsibility was taken for prescription, monitoring and follow up. The process was carefully documented and the patient recovered fully with no adverse effects. To date the only published data on the use of drotrecogin alpha in transplant recipients is a case series of three patients. Further published data may encourage review of the licence.
M3 - SCORING: Zeitschriftenaufsatz
VL - 62
SP - 282
EP - 285
JO - ANAESTHESIA
JF - ANAESTHESIA
SN - 0003-2409
IS - 3
M1 - 3
ER -
